The Indian IPO grocery has kicked off 2025 with a promising start, as Standard Glass Lining Ltd. has recently resolve its initial public offering (IPO). The company, specializing in high-quality equipment for pharmaceutical and chemical sectors, has garner significant attention from investors. Hither, we turn over into the contingent of the Standard Glass Lining IPO GMP (Grey Market Premium) and its implication for potential investors.
Company Overview
Standard Glass Lining Ltd. has built a report for providing turnkey resolution since its inception in 2012. The fellowship sharpen on custom-make solutions for pharmaceutical and chemical producer, utilise cloth such as glass-lined material, unsullied steel, and nickel alloy. Their key offering include response systems, depot and separation equipment, and dry out scheme, catering to big names like Cadila, Laurus Labs, and Piramal Pharma[1].
Fiscal Performance
The company’s financial functioning over the retiring three twelvemonth shows significant growth in plus, doubling from ₹300 Cr in 2020 to ₹756 Cr in 2022. Nevertheless, tax income growth has been slower, fire some concerns. Net Profit margins have continue steady at around 10-11%, which is reproducible but lacks improvement[1].
IPO Details
The Standard Glass Lining IPO unfold on January 6, 2025, and closed on January 8, 2025. Key point include:
– Face Value: ₹10 per share
– * Price Band: ₹133 to ₹140 per share
– * Lot Size: 107 shares
– Total Issue Size: ₹410 Cr (equally split up between fresh issue and offer for sale)
– Use of Funds:** Capex requirements, debt reduction, strategic investing, and world-wide corporate purposes[1][3].
Market Response
The IPO have an overwhelming response, oversubscribed by 185. 48 sentence. Roughly 52, 39, 243 applications programme were received from several platforms like Zerodha, Lemon, Groww, and more. The allotment status was expel on January 9, 2025, and the shares are set to list on January 13, 2025[3].
GMP Analysis
The Grey Market Premium (GMP) for Standard Glass Lining IPO stands at ₹96 (44%), signal a strong need for the contribution. Accord to industry experts, this gamey GMP evoke potential listing amplification, with some betoken a 40-50% addition post-listing[1][3].
Expert Insights
Ibor Wasne, a SEBI-register research analyst, notes, “While Standard Glass has solid fundamental frequency, the sudden reserve depletion due to a ₹120 Cr dividend declaration before the IPO enhance some concerns. It’s crucial to take apart beyond the hype and see the long-full term potential. “
Conclusion
The Standard Glass Lining IPO GMP reflects the food market’s optimism about the troupe’s future medical prognosis. With a substantial demand and potential itemization gains, investor are keenly watch over the listing on January 13, 2025. However, it’s indispensable to conceive the financial operation, use of investment trust, and potential peril before making investment decision. As the pharmaceutical sector proceed to get post-COVID, Standard Glass Lining’s customized solutions could offer substantial growth opportunities. Investor should remain cautious and conduct thorough research before seat in this promising IPO.
Future Developments
The itemization of Standard Glass Lining IPO will be a critical result to keep an eye on, as it will plant the quality for succeeding IPOs in 2025. The fellowship’s performance post-listing will be closely supervise, and any pregnant developments will be crucial for investors to consider.
In conclusion, the Standard Glass Lining IPO GMP indicates a strong marketplace demand, but investor should approach with caution, considering both the potential addition and the underlying peril. As the INITIAL OFFERING grocery store continues to evolve, it’s all important to stay informed and induce informed investiture decisions.
